BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment for chronic myeloid leukemia. Although these agents are normally safe and effective, they can cause side effects that lead to intolerance and necessitate switching to an alternative treatment. In this review, we describe side effects that occur during treatment with imatinib, nilotinib or dasatinibFthe currently approved TKI treatments for chronic myeloid leukemiaFincluding class effects and key differences in safety profiles. We also describe how common side effects can be effectively managed and offer a working definition of intolerance that may be useful to clinicians when they consider switching between TKIs.
Introduction
Current treatment of chronic myeloid leukemia (CML) is based on tyrosine kinase inhibitors (TKIs) that target the constitutively activated, oncogenic fusion protein BCR-ABL. BCR-ABL, the product of the Philadelphia chromosome, is both a marker of the disease and crucial in its pathogenesis. 1 Imatinib was the first TKI licensed for the treatment of CML and is approved for treating newly diagnosed CML in all phases. 2 Results from the pivotal phase III International Randomized Study of Interferon vs STI571 (IRIS), which now has follow-up extending to 8 years, have shown that first-line treatment with imatinib at an initial dose of 400 mg per day confers long-term benefit to most patients with chronic phase (CP) CML. 3, 4 Responses have also been reported following imatinib dose escalation to 600-800 mg per day in a proportion of patients who failed initial therapy with imatinib 400 mg per day. [5] [6] [7] Recently revised recommendations from the European LeukemiaNet suggest that outside of clinical trials, imatinib should be continued indefinitely in optimal responders. 8 However, a significant proportion of patients are unable to achieve optimal responses to first-line imatinib therapy because of resistance (often caused by the acquisition of imatinibinsensitive BCR-ABL mutants) or intolerance. 9, 10 Following the approval of imatinib, a second generation of TKIs targeting BCR-ABL was developed. Nilotinib and dasatinib are approved treatment options that are recommended by the European LeukemiaNet as options in cases of failure, suboptimal response or intolerance to first-line imatinib. 8 Nilotinib is an analog of imatinib with 20-fold greater potency and increased selectivity for unmutated BCR-ABL compared with imatinib in vitro. 11 Nilotinib also inhibits the platelet-derived growth factor receptor and c-Kit. 12 Nilotinib 400 mg twice daily is approved for the treatment of patients with CP or accelerated phase CML who are intolerant or resistant to first-line treatment, including imatinib. 13 Dasatinib, which is structurally unrelated to imatinib, is 325-fold more potent than imatinib at inhibiting unmutated BCR-ABL in vitro. It is less selective than nilotinib for BCR-ABL. In addition to BCR-ABL, c-Kit and platelet-derived growth factor receptor, dasatinib also inhibits SRC family kinases, which may at least in part mediate clinical resistance to imatinib and nilotinib, and the ephrin-A receptor. 11, [14] [15] [16] [17] [18] [19] Both nilotinib and dasatinib inhibit most imatinib-resistant BCR-ABL mutations in vitro. 11, 12, 20 Dasatinib 100 mg once daily and 140 mg once daily are licensed for the treatment of patients with CP or accelerated phase/blast-phase (BP) CML, respectively, who are intolerant or resistant to first-line therapy, including imatinib. 21 Both dasatinib and nilotinib have well-characterized efficacy and safety profiles in the first-and second-line setting. [22] [23] [24] [25] [26] [27] [28] [29] Similar to imatinib, patients receiving nilotinib or dasatinib may experience intolerance, and intolerance to any TKI represents a barrier to effective treatment. It is widely recognized that severe (grade 3-4) toxicities may dictate a change or interruption in therapy, but these measures may also be required in the case of chronic grade 2 adverse events (AEs). However, efficient management of AEs may reduce the occurrence of intolerance. Here, similarities and differences in the safety profiles of TKIs approved for treating CML are reviewed, focusing on data in patients with CP CML. Methods of AE management are also suggested. A working definition of intolerance is provided that clinicians may find useful.
Intolerance: when does an AE become a requirement to change therapy? inferior efficacy to imatinib for treating patients with CP CML. 34 Consequently, AEs experienced with imatinib were accepted by patients and physicians to a far greater degree than today and symptomatic management had a major role in patient care. 31 Today, patients experiencing significant AEs on imatinib may be switched to dasatinib or nilotinib, and there is, therefore, less need or willingness to accept imatinib-associated AEs.
Intolerance is also encountered with nilotinib or dasatinib therapy. Two separate trials of second-line treatment for CP CML have reported results with a minimum follow-up of 24 months. In the first trial, after 6 months of follow-up, 15% of patients had discontinued nilotinib 400 mg twice daily for toxicity related or unrelated for receiving the study drug. 22 After a minimum follow-up of 24 months, 58% of patients had their treatment interrupted and 19% of patients discontinued treatment as a result of AEs. 35 In the second trial, after a minimum of 6 months of follow-up, 4% of patients had discontinued dasatinib for treatment-related toxicity only. 36 After a minimum follow-up of 2 years, the toxicity-related discontinuation rate for dasatinib was 11 and 62% of patients had their treatment interrupted. 29 Dasatinib and nilotinib are also being studied as first-line treatments for patients with CP CML. In a randomized phase III trial of imatinib 400 mg once daily versus nilotinib 300 mg twice daily versus nilotinib 400 mg twice daily, rates of discontinuationFbecause of side effectsFwere 7, 5 and 9%, respectively, after a median duration of treatment of 14 months 28 (discontinuations due to laboratory abnormalities were not stated). In 2 separate single-arm phase II studies, 7 and 3% of patients had discontinued nilotinib 400 mg twice daily because of side effects after 17 and 24 months of follow-up, respectively. 37, 38 In a randomized phase III study of dasatinib 100 mg once daily versus imatinib 400 mg once daily, rates of discontinuation due to toxic events were 5 and 4%, respectively, after a median treatment duration of 14 months. 27 In a single-arm phase II trial of dasatinib, 5% of patients had discontinued 100 mg once daily because of side effects after a median of 24 months of followup. 39 Although a direct comparison is not available, these data suggest that the rate of discontinuation because of side effects is similar with dasatinib and nilotinib.
Intolerance to second-generation TKIs can sometimes result from cross intolerance with imatinib, that is, the reemergence of the same grade 3-4 AE on nilotinib or dasatinib that led to discontinuation of imatinib. In the nilotinib phase II trial in patients with CP CML, 7/42 (17%) patients who had hematological intolerance to imatinib recorded the same grade 3-4 hematological AE (thrombocytopenia) on nilotinib, and discontinued nilotinib therapy. 40 In the dasatinib phase III trial in patients with CP CML, 6/46 (13%) patients had hematological cross intolerance on dasatinib 100 mg once daily and subsequently discontinued dasatinib. 41 However, nonhematological cross intolerance to imatinib was uncommon with both nilotinib (2/109; 2%) and dasatinib 100 mg once daily (9/225; 4%). 40, 41 Although data from clinical trials are useful indicators of the tolerability of different TKIs, they cannot be used for true comparison because of different trial inclusion criteria and patient characteristics. An example of this are the entry criteria for key second-line trials for nilotinib and dasatinib in which imatinib intolerance was defined differently on the basis of the previous response to imatinib (Table 1) . 22, 29 Managing AEs to avoid intolerance
The incidence and severity of several types of AEs differ between the TKIs, although there are also other AEs that occur with all agents, indicating probable class effects. Identifying and managing toxicities is key to ensuring long-term patient benefit from therapy, and understanding the types of AEs that are likely with a particular agent can assist with early identification and more effective management. These toxicities (hematological, fluid retention, cardiac, metabolic and gastrointestinal (GI)) and their management are discussed.
Hematological AEs
Cytopenias are the most commonly occurring events in patients with CML receiving BCR-ABL inhibitors. Grades of severity for different cytopenias have been defined by the National Cancer Institute. 42 After 18 months of follow-up, patients with CP CML treated with first-line imatinib 400 mg per day in the IRIS study had cumulative rates of grade 3-4 neutropenia and thrombocytopenia of 14 and 8%, respectively. 34 Cytopenia occurs at higher rates in patients treated with nilotinib or dasatinib after previous imatinib treatment. After a minimum follow-up of 24 months, grade 3-4 neutropenia and thrombocytopenia were recorded in 31 and 30% of patients, respectively, who received nilotinib 800 mg per day, 35 and 35 and 23%, respectively, of patients who received dasatinib 100 mg once daily. 29 However, in studies of second-generation agents administered as first-line treatment in CP CML, rates of grade 3-4 cytopenia were lower for both nilotinib (neutropenia 4-12%, thrombocytopenia 2-12%) and dasatinib (neutropenia 21%, thrombocytopenia 10-19%). 27, 28, 37, 39, 43 Cytopenia during BCR-ABL inhibitor therapy is thought to reflect a reduced reserve of residual, healthy Philadelphia chromosome-negative bone marrow that is unable to reconstitute peripheral blood counts, rather than toxicity towards normal hematopoietic cells per se. 44 This may explain the higher rates of cytopenia seen in patients with advanced phases of CML (Table 2) . 24, 26, [45] [46] [47] It should also be recognized that previous therapies may have compromised the bone marrow reserve of patients beginning TKI therapy. It is possible that TKIs might suppress normal hematopoietic stem cell function and in vitro studies have suggested that TKIs, particularly dasatinib, have varying inhibitory effects against platelets, 48 although dasatinib-mediated effects were found to be rapidly reversible with interruption. 49 Furthermore, imatinib and dasatinib have been associated with low rates of cytopenia in the treatment of nonhematological malignancies, which argues against a direct toxic effect toward normal hematopoiesis. 50, 51 Most cytopenias occur during the first few months of treatment, are self limiting, and are mild-to-moderate in severity (grade 1-2). However, serious events can occasionally emerge after prolonged treatment meaning that ongoing monitoring is needed. Blood counts should be monitored weekly in the first month of treatment, monthly during month 2 and 3, and every Table 1 Definitions of imatinib intolerance as defined in key trials of nilotinib and dasatinib.
SPOTLIGHT

22,29
Nilotinib trials Dasatinib trials
Discontinuation of treatment because of gradeX3 toxicity, recurrent/persistent grade 2 nonhematological toxicity, or persistent grade 4 hematological toxicity and lack of a major cytogenetic response at the time of study entry GradeX3 toxicity, as least possibly related to imatinibX400 mg per day, which led to discontinuation of therapy
Management of adverse events in chronic myeloid leukemia E Jabbour et al 3 months thereafter. Patients should also be educated to recognize and promptly report relevant symptoms, including fever (particularly in conjunction with infection), fatigue, shortness of breath and easy bruising. 52 Cytopenias are primarily managed through dose modification or interruption and prescribing information for each agent specifies the appropriate schedule adjustments for cytopenias of varying severity (Table 3) . Supportive treatment for cytopenias, in conjunction with dose modification, may assist with managing more severe AEs. The use of growth factors, such as granulocyte colony-stimulating factor, interleukin-11 and erythropoietin has been suggested in patients with CML receiving TKI therapy, 53 although these agents are not approved in this indication and recent guidelines do not support the use of erythropoietic-stimulating agents in myeloid malignancies. 54 
Fluid retention events
All three clinically available BCR-ABL inhibitors are associated with fluid retention events, although incidences and clinical presentations differ. In imatinib-treated patients with CP CML, a fluid retention AE of any type was observed in 62% of patients, including 60% who developed superficial edema and 7% who had other fluid retention AEs, such as pleural effusion, ascites, pulmonary edema or pericardial effusion. Edema with imatinib was most frequently periorbital or in lower limbs. However, severe fluid retention AEs were relatively uncommon, with grade 3-4 events occurring in o1% of patients. 31 After 2 years of follow-up in the phase II study of nilotinib in patients with CP CML and previous imatinib-treatment, drug-related peripheral edema of any grade occurred in 6% of patients (0% grade 3-4) and pleural effusion occurred in 1% (grade 3-4 in 0.3%). 35 In the phase III study of nilotinib versus imatinib as first-line treatment for patients with CP CML, patients receiving imatinib were more likely to experience all-grade peripheral edema, eyelid edema and periorbital edema (14, 13 and 12%, respectively), than patients receiving dasatinib 300 mg twice daily (5, 1 and o1%, respectively) or dasatinib 400 mg twice daily (5, 2 and 1%, respectively). 28 After 2 years of follow-up with dasatinib 100 mg once daily in patients with CP CML and previous imatinib treatment, drugrelated superficial edema of any grade occurred in 17% (0% grade 3-4), pleural effusion occurred in 14% (1% grade 1, 10% grade 2, 2% grade 3, 0% grade 4), and pericardial effusion occurred in 2% (1% grade 3-4). 29, 55 In the phase II study of patients with CP CML as first-line therapy, pleural effusion was recorded in 2/31 patients (6%) treated with dasatinib 100 mg once daily, which was grade 3 in one patient. 39 In the phase III comparison of dasatinib and imatinib as first-line treatment of patients with CP CML, pleural effusion was observed in 26/259 (10%) patients receiving dasatinib. All events were grade 1-2. No pleural effusion was experienced by patients receiving imatinib; however, all-grade fluid retention events in general were more frequently experienced by patients receiving imatinib (42%) than by those receiving dasatinib (19%). 27 The pathogenesis of dasatinib-associated pleural effusion remains unclear. It has been suggested that the pathogenesis involves inhibition of platelet-derived growth factor receptors or expansion of cytotoxic T and natural killer (NK) cell populations. 56 Support for an immune-mediated pathogenesis is given by the association of pleural effusions with other immunemediated reactions, including a history of autoimmune disease or skin rash during previous imatinib therapy, and high levels of lymphocytes in pleural fluid and tissue in affected patients. [57] [58] [59] Furthermore, dasatinib has been associated with clonal expansion of T-cells and NK cells. 60, 61 A link between such Abbreviation: CML, chronic myeloid leukemia.
SPOTLIGHT
Management of adverse events in chronic myeloid leukemia E Jabbour et al lymphocytosis and complete and durable remission in some patients has been suggested. 60 The incidence of severe fluid retention AEs is low, but significant and regular monitoring is needed. With imatinib, patients older than 65 years and those with cardiac disease or renal insufficiency are more likely to experience fluid retention. 32 With dasatinib treatment in patients who previously received imatinib, various risk factors for pleural effusion have been identified using multivariate analyses and include older age, preexisting cardiac disease, hypertension, hypercholesterolemia, autoimmune disease or skin rash while on imatinib. 55, 58, 59 In addition, pleural effusion on dasatinib occurs more frequently in patients treated with dasatinib in advanced versus CP CML, and was more common in patients who received the now defunct twice-daily dosing versus current once-daily dosing. In a small study of 48 patients with any-phase CML (46% CP, 14% accelerated phase and 40% BP) who received dasatinib 15-180 mg once or twice daily in phase I and II studies, it was found that pleural effusion was more than twice as likely in patients with a history of cardiac disease (72 versus 29%; P ¼ 0.0003) or hypertension (57 versus 27%; P ¼ 0.001) than in those without these risk factors. 58 A larger study is required to establish independent risk factors for pleural effusion at current dose schedules in the various stages of CML.
All patients, particularly those with risk factors, should be monitored closely for symptoms suggestive of fluid retention. Monitoring should include regular assessment of body weight, heart-and lung-associated symptoms and peripheral tissue tone. Rapid weight gain should be a signal for careful investigation and treatment. A chest X-ray should be performed in patients with symptoms suggestive of pleural effusion (for example, dyspnea or dry cough). Patients should also be educated to recognize and report relevant symptoms.
Fluid retention AEs are normally reversible. Evidence of peripheral edema or rapid weight gain indicates that diuretic therapy should be initiated or increased in dose if already prescribed. In severe cases, TKI treatment should be suspended until the edema is cotrolled, with the dosage reduced when therapy is restarted. Periorbital edemas, typically experienced during imatinib therapy, may be reduced by limiting salt intake, and topical hydrocortisone or phenylephrine may be beneficial. 31 Pleural effusion is normally manageable through dose interruption/reduction and supportive measures, including diuretics and steroids (Figure 1) . 54, 55, 58, 62, 63 Considering the short half life of dasatinib, introducing a weekend holiday (5 days/week schedule) to allow recovery from the off-target activity has been investigated in an attempt to reduce side effects. 64 Prospective studies to confirm this hypothesis are in preparation.
Cardiotoxicity
Cardiotoxicity is a rare, but potentially serious complication of therapy with all BCR-ABL inhibitors. 65, 66 Estimating the incidence of cardiac toxicity with these agents is hampered because patients with cardiac comorbidity were typically excluded from clinical trials. In retrospective analyses of clinical trials or single-institution databases, the estimated frequency of congestive heart failure or left ventricular dysfunction during imatinib therapy for CML was 0.5-1.1%. [67] [68] [69] In large analyses of patients entered into clinical studies of imatinib, systolic heart failureFconsidered by the investigators to be possibly or Table 3 Recommendations for dose modification in the case of cytopenia according to prescribing information. Management of adverse events in chronic myeloid leukemia E Jabbour et al probably related to imatinib therapyFoccurred in 0.5-0.6% of patients. 67, 68 Congestive heart failure during imatinib treatment of CML usually occurs in elderly patients with preexisting cardiac problems or other comorbidities. 50, 67 It is possible that the incidence of these events may be higher in the general population, in which the incidence of severe cardiac conditions is higher than in study populations. In patients receiving imatinib treatment for GI stromal tumor or other sarcomas, heart failure was again rare (o1% of patients); however, other severe cardiac events (usually effusions or edema) were reported in 8% of patients. These events responded to medical management and generally did not require treatment interruption or discontinuation. 70 Grade 1-2 congestive heart failure was noted in 4% of patients with myeloid BP CML treated with dasatinib 140 mg once daily. 62 The US prescribing information for nilotinib includes a black box warning relating to QT prolongation and sudden deaths. 71 QT prolongation has been noted during second-line treatment with both nilotinib and dasatinib, although the total incidence of QTcF 4500 msec was less than 1% for each agent. 62, 71, 72 To date, there have been no instances of severe QT prolongation during first-line nilotinib or dasatinib treatment. 27, 28, 37, 39, 43 During the nilotinib phase II trial program, sudden death occurred in 0.6% of patients, with a similar incidence recorded in an expanded-access program. 71 The early occurrence of the deaths after nilotinib initiation suggested that ventricular repolarization abnormalities may have contributed. 71 Contraindications for nilotinib therapy include hypokalemia, hypomagnesemia or long QT syndrome. 71 Because taking nilotinib with food may lead to unpredictably high peak plasma levels (increased absorption in the presence of fat) that significantly increase the risk of QT prolongation, no food should be consumed 2 h before and 1 h after each twice-daily dose. Dasatinib should be administered with caution to patients who are deemed at risk of developing prolongation of QTc.
SPOTLIGHT
Because of the potential consequences of cardiac AEs, patients with CML and existing cardiac disease or cardiac risk factors should be closely monitored during BCR-ABL inhibitor therapy, particularly patients with a history of cardiac conduction abnormalities. Patients should be weighed regularly and assessed for signs of fluid retention, for example, unexpected weight gain. 66 With nilotinib, it is recommended that ECGs are performed at baseline, 7 days after initiation of treatment, periodically throughout therapy and following dose adjustments, and that electrolyte levels are monitored periodically throughout therapy. Electrolyte abnormalities should be corrected before both nilotinib and dasatinib therapy. During BCR-ABL inhibitor treatment, strong CYP3A4 inhibitors should be used with caution (imatinib) or avoided (nilotinib and dasatinib). Potential cardiotoxicity associated with previous therapies should also be considered. The management steps for cardiotoxicity are summarized in Table 4 .
Metabolic AEs
Markers of hepatic toxicity or abnormality, such as elevated aspartate aminotransferase (AST) and alanine aminotransferases and bilirubin, have been seen during BCR-ABL inhibitor therapy. In patients with CP CML treated with nilotinib after imatinib failure, grade 3-4 elevations in alanine aminotransferase and AST developed in 3-4% and grade 3-4 bilirubin elevations developed in 7%. 35 Discontinuation of second-line nilotinib therapy resulting from hepatobiliary AEs remains uncommon (o1%). 35 With first-line nilotinib, grade 3 elevations of alanine aminotransferase (0-98%), AST (0-3%), and bilirubin (7-16%) were also seen. 37, 43 Increased liver enzymes are the most frequent cause of treatment interruption in patients receiving first-line nilotinib therapy (13/61 patients; 21%). 37 However, polymorphisms in the gene coding for uridine diphosphate glucuronosyltransferase 1A1, which predisposes to Gilbert syndrome, predict for susceptibility to nilotinibinduced hyperbilirubinemia, supporting the argument that these laboratory abnormalities observed during nilotinib therapy do not reflect true hepatotoxicity. 
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In patients with CP CML treated with first-line imatinib, grade 3-4 elevations in alanine aminotransferase or AST occurred in 5% of patients and grade 3-4 elevations in bilirubin occurred in 1%. 50 Occasional cases of imatinib-induced fatal liver failure have been reported. [74] [75] [76] [77] During dasatinib-treatment of CP CML after imatinib failure or first line, grade 3/4 elevated AST, AST or bilirubin occurred in 0-o1% of patients. 39, 62 Hepatic toxicity or abnormality may be self limiting or can be managed with dose interruption/adjustment, although successful use of corticosteroids for imatinib-associated hepatic toxicity has also been reported. [78] [79] [80] With both imatinib and nilotinib, liver function tests should be performed monthly or as clinically indicated. Patients with impaired liver function at baseline should receive a lower starting dose of nilotinib.
Pancreatic abnormalities have been reported during nilotinib therapy. In the nilotinib phase II study in patients with CP CML and previous imatinib treatment, grade 3-4 serum lipase elevation was reported in 18% of patients and grade 3-4 hyperglycemia was reported in 12%. 35 In most cases this was self limiting, although frank pancreatitis was reported in 1% of patients. 22 In an expanded access study with nilotinib, grade 3-4 serum lipase elevation was experienced by 6% of patients, and pancreatitis was reported in 2%. The discontinuation rates due to either event were o1%. 72 With first-line nilotinib treatment, rates of grade 3-4 lipase elevation and hyperglycemia seemed to be slightly lower (3-8 and 3%, respectively). 28, 37, 43 Nilotinib should be used with caution in patients with a history of pancreatitis and lipase levels should be checked periodically.
Altered mineral metabolism occurs with all BCR-ABL inhibitors. Hypophosphatemia is common during imatinib therapy, occurring in approximately 50% of treated patients. [81] [82] [83] [84] In patients with CP CML who received either dasatinib or nilotinib, grade 3-4 hypophosphatemia was seen in 10% of patients. 62, 71 Hypokalemia, hyperkalemia, hyponatremia and hypocalcemia have also been noted during BCR-ABL inhibitor therapy. Because of the risks of cardiotoxicity, electrolyte levels should be corrected before therapy, and for nilotinib, levels should be periodically monitored during therapy, as discussed in the cardiotoxicity section.
GI AEs
Low-grade GI disturbances are observed in approximately 25-50% of patients receiving first-line and second-line BCR-ABL inhibitor treatment for CML, although the incidence of grade 3-4 events is low (0-3%), particularly during first-line treatment with nilotinib or dasatinib. 27, 28, 37, 39, 43, 50, 62, 71 Patients may experience a reduction in GI symptoms if imatinib or dasatinib tablets are taken with a large meal and water. However, it should be stressed that nilotinib has a fasting requirement for administration. 71 Appropriate supportive treatments, such as antidiarrheal or antiemetic medications, may assist with management. In the case of severe, unresponsive GI AEs, TKIs should be withheld.
Other common AEs associated with BCR-ABL inhibitor treatment
Skin complaints have been seen during therapy with BCR-ABL inhibitors. During first-line imatinib treatment of CP CML, rash was noted in 34 and pruritus in 7%. 34 In patients with CP CML and previous imatinib treatment, rash and pruritus occurred with nilotinib in 31 and 26%, respectively, 35 and with dasatinib 100 mg once daily in 17 and 10%, respectively. 29 In the phase III study of first-line nilotinib and imatinib, all-grade pruritus and rash was observed in 5 and 11% of patients receiving imatinib, 13 and 36% of patients receiving nilotinib 400 mg twice daily and 15 and 31% of those receiving nilotinib 300 mg twice daily, respectively. 28 In the phase III comparison of first-line imatinib and dasatinib, all-grade rash was reported in 17 and 11% of patients, respectively 27 (incidences of pruritus not reported). In all cases, rates of grade 3-4 skin AEs were 3% or less. These reactions are most likely to be nonallergic and self limiting, and can be managed with antihistamines or topical steroids. Oral steroids should be reserved for the most severe cases. 31, 85 During imatinib treatment, musculoskeletal complaints are common. In the IRIS trial, musculoskeletal pain and muscle cramps were reported by nearly 50% of patients, including grade 3-4 musculoskeletal pain in 5%, and myalgia was reported by 24%. 50 However, these AEs seem to be less problematic with second-generation agents. With nilotinib Table 4 Precautions and management of cardiotoxicity during TKI therapy according to the prescribing information. 50, 62, 71 Agent
SPOTLIGHT
Dose modification Precautions
Imatinib On the emergence of a severe event, withhold until the event has resolved. Resume at an appropriate dose, depending on initial severity of event.
Carefully monitor any patient with or at risk for cardiac failure. All patients with signs or symptoms of cardiac failure should be evaluated and treated.
Nilotinib QTc 4480 ms: (1) withhold therapy, correct serum potassium and magnesium levels if below normal, and review concomitant medication; (2) resume at previous dose in o2 weeks if QTc returns to o450 ms and o20 ms of baseline; (3) reduce dose to 400 mg per day if QTc 450-480 ms after 2 weeks; (4) discontinue if QTc returns to 4480 ms after dose reduction; (5) repeat ECG assessment approx. 7 days after any dose adjustment Do not administer to patients with long QT syndrome. Do not administer drugs known to prolong QT, and strong CYP3A4 inhibitors. Correct hypokalemia or hypomagnesemia before administration, and periodically monitor serum electrolyte levels during therapy. Perform ECGs at baseline, 7 days after treatment start, periodically as indicated clinically and after any dose adjustment.
Dasatinib
On the emergence of a severe event, withhold until the event has resolved or improved. Resume at an appropriate dose, depending on initial severity of event.
Administer with caution to patients with or at risk of QTc prolongation: those with hypokalemia, hypomagnesemia or congenital long QT syndrome; or taking medicines known to prolong QT, including antiarrhythmic drugs and cumulative high-dose anthracycline therapy. Correct hypokalemia or hypomagnesemia before administration.
Management of adverse events in chronic myeloid leukemia E Jabbour et al treatment of patients with CP CML and previous imatinib treatment, muscle spasm and myalgia occurred in 11 and 14%. 71 With dasatinib 100 mg once-daily treatment of CP CML after imatinib, musculoskeletal pain and myalgia occurred in 19 and 13% of patients, respectively. 62 In the first-line setting for patients with CP CML, any-grade muscle spasm was experienced by 24% of patients receiving imatinib, 7% of patients receiving nilotinib 300 mg twice daily, and 6% of those receiving nilotinib 400 mg twice daily. Incidences of any-grade myalgia were 10% in all arms. 28 In the phase III study of firstline dasatinib and imatinib, incidences were higher in the imatinib arm for any-grade myalgia (12 versus 6%), muscle inflammation (17 versus 4%) and musculoskeletal pain (14 versus 11%). 27 Grade 3-4 events were infrequent with both nilotinib and dasatinib (0-1%). 27, 28 Symptomatic relief from muscle cramps can frequently be achieved with calcium and magnesium supplements or quinine. 31 Dasatinib has been associated with bleeding-related events, mostly related to severe thrombocytopenia, which have included fatal central nervous system hemorrhages. The incidence of grade 3-4 hemorrhage in patients with CP CML receiving second-line dasatinib 100 mg once daily has been 1% (GI bleeding only). 62 In the phase III study of first-line dasatinib and imatinib in patients with CP CML, all-grade bleeding events were found in 5% of patients in both arms; grade 3-4 events were experienced by 1/259 patients in the dasatinib arm and 2/260 patients in the imatinib arm (o1% in both cases). 27 Dasatinib should, therefore, be used with caution in patients with a history of bleeding or those receiving drugs that inhibit platelet function or anticoagulants. Severe GI hemorrhage may require treatment interruption and transfusion. 62 With all three agents, fatigue or headache occurs in approximately 25-35% of patients, reaching grade 3-4 in 1-3% of patients. Fatigue may be related to anemia, which is often observed during early treatment. Headache can be managed with standard analgesics.
Adherence to BCR-ABL inhibitors
Nonadherence is a known problem among patients with chronic disease receiving long-term medication. 86, 87 With imatinib treatment, an analysis of patient-level pharmacy claims data in 4043 imatinib-treated patients (CML or GI stromal tumors) found that patients with CML took an average of 78% of their prescribed imatinib therapy during the 24-month study period. 88 In a separate analysis of pharmacy claims, the adherence rate to imatinib at doses of 400 to less than 600 mg per day was 66%, which decreased to 52% for patients prescribed 600 to less than 800 mg per day (Po0.0001). 89 A retrospective analysis of electronic healthcare claims data from a US-managed care provider found that 31% of 267 adult patients with CML interrupted their treatment, that is, failed to refill imatinib within 30 days from the run-out date of the prior prescription. 90 Nonadherence to treatment is likely to lead to reduced trough drug concentrations, which are associated with reduced efficacy. 91, 92 Furthermore, studies have shown that patients with CML who have lower levels of adherence to imatinib treatment have significantly worse treatment responses. 93, 94 Data from other chronic diseases indicate that patient counseling techniques may enhance adherence. 95 Patients should be educated on the benefits of adhering to treatment regimens and on the AEs to expect with treatment. Recommendations on how to manage less-serious AEs should also be provided.
Proposed definition of intolerance
Intolerance to any TKI should be regarded as a diagnosis, and consequently all efforts should be made to arrive at a correct diagnosis. A patient has intolerance to a TKI if one or more of the following criteria have been met: (i) any life-threatening grade 4 nonhematological toxicity; (ii) any grade 3/4 nonhematological toxicity that has recurred despite dose reduction and optimal symptomatic measures; (iii) any grade 2 nonhematological toxicity that persists for more than a month despite optimal supportive measures; or (iv) grade 3-4 hematological toxicity that is unresponsive to supportive measures and would require dose reductions below the accepted minimal effective dose.
Beyond these clear-cut definitions of intolerance there is a gray area governed as much by objective findings as by the availability of alternatives that may offer a better quality of life. Thus, in addition to the criteria proposed, intolerance could also be defined as any combination of nonhematological toxicities of any grade that persist despite optimal supportive measures and in the patient's and the physician's opinion compromise quality of life to such an extent that a change of therapy is justified.
Conclusions
Overall, BCR-ABL inhibitor treatments for CML are well tolerated. However, intolerance occurs in a significant proportion of patients and can limit the potential benefits of treatment. Estimating the incidence of intolerance in clinical practice is difficult. As second-generation agents become available, the proportion of patients discontinuing imatinib because of AEs is likely to be greater than the 5% seen in the IRIS trial. Furthermore, patients with several types of comorbidity were excluded from clinical trials, implying that populations encountered in clinical practice are likely to have a higher overall risk of toxicity and intolerance.
Several types of AE occur with all BCR-ABL inhibitors and seem to be class effects, including cytopenias, fluid retention, GI disorders, skin complaints, musculoskeletal pain, fatigue, headache and low rates of cardiac toxicity. Cytopenias probably reflect the antileukemic effects of TKIs in the setting of a limited reserve of normal hematopoiesis, rather than direct toxicity against healthy hematopoietic cells. Most nonhematological AEs occur at grade 3-4 in less than 2-3% of patients. Several AEs observed during second-line treatment with nilotinib or dasatinib have a reduced frequency and severity in patients receiving first-line treatment with these agents.
AEs that seem to be more problematic with certain agents include increased rates of superficial edema with imatinib, pleural effusion with dasatinib, lipase elevation and hyperglycemia with nilotinib, hepatic toxicity with imatinib and nilotinib and muscle cramps/pain with imatinib. Sudden death has been recorded rarely in patients who received nilotinib, potentially due to ventricular repolarization abnormalities, which may be more of a risk if nilotinib is taken without the required 2-h fast.
Comorbidities relevant to differences in AE profiles between agents should be considered when selecting treatment and this may become more important in future if second-generation agents are approved for first-line treatment. Specifically, in patients at high risk of pleural effusion (particularly those with a history of cardiac disease or hypertension) or bleeding events (especially those with a history of such events), nilotinib should be considered in the absence of nilotinib-resistant BCR-ABL mutations. For any patient experiencing AEs, maintenance of current therapy and appropriate AE management should be the
SPOTLIGHT
Management of adverse events in chronic myeloid leukemia E Jabbour et al first option, particularly when a patient is responding well to treatment. The potential loss of efficacy associated with dose reduction in response to a chronic AE should not be discounted. However, with early identification, dose adjustment and/or supportive care, most AEs associated with TKIs can be managed and should not affect treatment responses.
